Onesource Specialty Pharma Ltd
NSE:ONESOURCE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Bravada Gold Corp
OTC:BGAVF
|
CA |
|
A
|
Ascot Resources Ltd
OTC:AOTVF
|
CA |
|
C
|
Ceres Global Ag Corp
OTC:CERGF
|
US |
Onesource Specialty Pharma Ltd
Note Receivable
Onesource Specialty Pharma Ltd
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Onesource Specialty Pharma Ltd
NSE:ONESOURCE
|
Note Receivable
₹1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Divi's Laboratories Ltd
NSE:DIVISLAB
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Syngene International Ltd
NSE:SYNGENE
|
Note Receivable
₹1.3B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
12%
|
CAGR 10-Years
1%
|
|
|
A
|
Akums Drugs and Pharmaceuticals Ltd
NSE:AKUMS
|
Note Receivable
₹316.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sai Life Sciences Ltd
NSE:SAILIFE
|
Note Receivable
₹124m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
Anthem Biosciences Ltd
NSE:ANTHEM
|
Note Receivable
₹100.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Onesource Specialty Pharma Ltd
Glance View
Onesource Specialty Pharma Ltd is a IN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Bangalore, Karnataka and currently employs 525 full-time employees. The company went IPO on 2025-01-24. OneSource Specialty Pharma Limited is an India-based vertically integrated biopharma service company with the capabilities to develop and manufacture complex biologics, biosimilars and vaccines. The company operates as a specialty pharma pure-play contract development and manufacturing organization (CDMO). The firm specializes in prefilled syringes (with or without a safety device), dial and push variable and fixed dose pen injectors, pull push fixed dose pens and autoinjectors. Its integrated services offer comprehensive biologics solutions. The company supports the development of complex biologics, including microbial and mammalian cell line biopharmaceuticals, cell and gene therapy and ribonucleic acid (RNA) products. The firm caters to a variety of capsule shapes and sizes, as well as formulations, traditional softgels to enteric coated capsules, vegan alternatives, chewable formats, vaginal pessaries, liposomal capsules, applicaps, and suppositories.
See Also
What is Onesource Specialty Pharma Ltd's Note Receivable?
Note Receivable
1B
INR
Based on the financial report for Mar 31, 2025, Onesource Specialty Pharma Ltd's Note Receivable amounts to 1B INR.
What is Onesource Specialty Pharma Ltd's Note Receivable growth rate?
Note Receivable CAGR 1Y
41%
Over the last year, the Note Receivable growth was 41%.